Dopamine agonists and neuroprotection in Parkinson's disease

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Olanow, C Warren ^a   Jenner, Peter ^b   Brooks, David ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

CONFERENCE PAPER; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; MEDICAL LITERATURE; MEDICAL RESEARCH; NEUROLOGY; PUBLICATION;

EID: 0031716026     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440725     Document Type: Conference Paper

References (81)

1. Kartzinel R, Teychenne P, Gillespie MM, et al. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 1976;2:272-275
2. Calne DB, Burton K, Beckman J, Martin WR. Dopamine agonists in Parkinson's disease. Can J Neurol Sci 1984;11:221-224
3. Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206
4. Olanow CW, et al. A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47
5. McDonald RJ, Horowski R. Lisuride in the treatment of parkinsonism. Eur Neurol 1983;22:240-255
6. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992;19: 108-112
7. Olanow CW. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease. In: Olanow CW, Obeso JA, eds. Dopamine agonists in early Parkinson's disease. Tunbridge Wells, UK: Wells Medical, 1997:37-52
8. 3H]spiperone binding. Brain Res 1986;379:294-299
9. Pearce RKB, Banerji T, Jenner P, Marsden CD. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug-naïve MPTP-treated common marmosets. Br J Pharmacol 1996;118:37
10. Rinne UK. Brief communications: early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5 year follow-up. Neurology 1987;37:826-828
11. Olanow CW, Alberts M, Stajich J, Burch G. A randomized blinded study of low dose bromocriptine versus low dose carbidopa/levodopa in untreated Parkinson patients. In: Fahn S, Marsden D, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Vol II. New York: Macmillan Health Care, 1987:201-208
12. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038
13. Wheadon DE, Wilson-Lynch K, Kreider M. The efficacy and safety of ropinirole in early parkinsonian patients not receiving dopaminergic therapy - a multicenter double-blind study. Neurology 1996;46:159
14. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347
15. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. JAMA 1997;278:125-130
16. Rascol O. A double blind L-DOPA controlled study of ropinirole in de novo patients with Parkinson's disease. Neurology 1996;46:160
17. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease. Neurology [in press]
18. Halliwell B, Gutteridge J. Oxygen radicals and the nervous system. Trends Neurol Sci 1985;8:22-29
19. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37
20. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 1989;86:1398-1400
21. Spencer JPE, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 1995;6:1480-1484
22. +. Free Rad Biol Med 1992;13:581-583
23. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurosci 1991;101:198-203
24. Ziv I, Melamed E, Nardi N, et al. Dopamine induces apoprosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosc Lett 1994;170:136-140
25. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435
26. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:S161-170
27. Good P. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol [in press]
28. Spina MB, Cohen G. Exposure of striatal synaptosomes to l-dopa elevates levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-507
29. Spencer Smith T, Parker WD Jr, Bennett JP. L-DOPA increases nigral production of hydroxyl radicals in vivo: potential L-DOPA toxicity? Neuroreport 1994;5:1009-1011
30. Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-DOPA and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353: 246-250
31. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by DOPA and iron. Neurosci Lett 1992;140:42-46
32. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals: possible participation of levodopa. Adv Neurol 1993;60:242-250
33. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723
34. Mytilineou C, Han S-K, Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478
35. Basma AN, Morris EJ, Nicklas WJ, Geller HM. L-dopa cytotoxicity to PC12 cells in culture is via its autooxidation. J Neurochem 1995;64:825-832
36. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464
37. Steece-Collier K, Collier TJ, Sladek CD, Sladek JR. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990;110:201-208
38. Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′ deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204
39. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain. A selective increase in 8-hydroxyguanine in substantia nigra? J Neurochem 1997;69: 1196-1203
40. Alam ZI, Daniel SE, Lees AJ, et al. A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-1329
41. Hefti F, Melamed E, Bhawan J, Wurtman R. Long term administration of l-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195
42. Perry TL, Young VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43:990-993
43. Quinn N, Parkes JD, Janota I, et al. Preservation of substantia nigta neurons and locus coeruleus in patients receiving levodopa (2 gm) plus decarboxylase inhibitor over a four year period. Mov Disord 1986;1:65-68
44. Zeng B-Y, Lyras L, Pearce R, et al. Failure of chronic l-dopa administration to cause damage to the nigrostriatal system in normal monkeys. Neuroscience [in press]
45. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133
46. Ogawa N, Asanuma M, Kondo Y, et al. Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 1994;171:55-58
47. Han S-K, Mytilineou C, Cohen G. L-dopa up-regulates glutathione and protects mesencephalic cultutes against oxidative stress. J Neurochem 1996;66:501-510
48. Liu J, Mori A. Monoamine metabolism provides an antioxidant defense in the brain against oxidant- and free radical induced damage. Arch Biochem Biophys 1993;302:118-127
49. Tatton WG, Ju WYH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youdim MHB, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996:202-220
50. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity. J Neurochem 1997; 68:33-39
51. Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350:230-232
52. Tatton WG, Ju WYL, Holland DP, et al. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575
53. Ogawa N, Iwata E, Asanuma M, Nishibayashi S, Iida K. Oxidative stress and transcription factors. In: Packer L, Hiramatsu M, Yoshikawa T, eds. Free radicals in brain physiology and disorders. San Diego: Academic Press, 1996:131-140
54. Mytilineou C, Leonardi EK, Radcliffe P, et al. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther 1998; 284:700-706
55. Pardo B, Mena MA, Fahn S, de Yebenes JG. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 1993;8:278-284
56. Kokotos Leonardi ET, Cheng B, Radcliffe PR, Olanow CW, Cohen G, Mytilineou C. L-dopa and L-deprenyl protect against L-BSO induced cell death in cultured mesencephalic neurons [abstract]. Soc Neurosci Abst 1996;22:6786
57. Olanow CW, Fahn S, Muenter M, et al. A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47
58. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995; Suppl 45:231-238
59. Calne DB, Burton K, Beckman J, Martin WR. Dopamine agonists in Parkinson's disease. Can J Neurol Sci 1984;11:221-224
60. Carter AJ, Muller RE. Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72
61. Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 1995; 18:34-42
62. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro. Brain Res 1994;657:207-213
63. Saiardi A, Bozzi Y, Baik J-H, Borrelli E. Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 1997;19:115-126
64. Kelly MA, Rubinstein M, Asa SL, et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997;19:103-113
65. Yin D, Kondo S, Takeuchi J, Morimura T. Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett 1994;339:73-75
66. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038
67. Nishibayashi S, Asanuma M, Kohno M, Gómez-Vargas M, Ogawa N. Scavenging effects ot dopamine agonists on nitric oxide radicals. J Neurochem 1996;67:2208-2211
68. Clow A, Freestone C, Lewis E, et al. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett 1993;164:41-43
69. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurol Sci 1989;12:366-375
70. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurol Sci 1990;13:281-289
71. Piallat B, Bennazouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioral and immunohistochemical studies. Eur J Neurosci Suppl 1996;8:1408-1414
72. Saji M, Blau AD, Volpe BT. Prevention of transneuronal degeneration of neurons in the substantia nigra reticulata by ablation of the subthalamic nucleus. Exp Neurol 1996;141:120-129
73. Gassen M, Glinka Y, Pinchasi B, Youdim MB. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 1996;308:219-225
74. 2-induced cell death. Adv Pharmacol 1998;42:320-324
75. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997;104:209-228
76. Carvey PM, Ling Z-D. The effects of pramipexole on mesencephalic-derived neurotrophic activity. Neurology [in press]
77. Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch Int Pharmacodyn 1995;329:221-230
78. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Ageing 1992;13:339-351
79. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol 1995;38:771-777
80. Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado study discontinued. Eur J Clin Pharmacol 1992; 43:357-363
81. Olanow CW, Obeso JA. Dopamine agonists in early Parkinson's disease. Tunbridge Wells, UK: Wells Medical, 1997